Skip to main content
TipRanks
Go Ultimate75% OFF

PTC Therapeutics (P91) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

PTC Therapeutics has a market cap or net worth of CHF 4.28B. The enterprise value is CHF 3.92B.

Market Cap
CHF 4.28B
Enterprise Value
CHF 3.92B

Share Statistics

PTC Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
―
Owned by Insiders
3.02%
Owned by Institutions
87.90%

Financial Efficiency

PTC Therapeutics’s return on equity (ROE) is -3.32 and return on invested capital (ROIC) is 33.37%.

Return on Equity (ROE)
-3.32
Return on Assets (ROA)
0.24
Return on Invested Capital (ROIC)
33.37%
Return on Capital Employed (ROCE)
0.44
Revenue Per Employee
1.75M
Profits Per Employee
688.84K
Employee Count
991
Asset Turnover
0.60
Inventory Turnover
0.90

Valuation Ratios

The current PE Ratio of PTC Therapeutics is -46.44. PTC Therapeutics’s PEG ratio is 0.66.

PE Ratio
-46.44
PS Ratio
4.40
PB Ratio
-26.56
Price to FCF
-133.91
Price to Operating Cash Flow
484.28
PEG Ratio
0.66

Income Statement

In the last 12 months, PTC Therapeutics had revenue of 1.73B and earned 682.64M in profits. Earnings per share was 8.58.

Revenue
1.73B
Gross Profit
1.66B
Operating Income
856.51M
Pretax Income
696.62M
Net Income
682.64M
EBITDA
887.66M
Earnings Per Share (EPS)
8.58

Cash Flow

In the last 12 months, operating cash flow was 10.49M and capital expenditures -48.45M, giving a free cash flow of -37.96M billion.

Operating Cash Flow
10.49M
Free Cash Flow
-37.96M
Free Cash Flow per Share
-0.45

Dividends & Yields

PTC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-0.75%
Earnings Yield
-2.10%

Important Dates

PTC Therapeutics upcoming earnings date is Feb 23, 2027, TBA (Not Confirmed).

Last Earnings Date
Oct 29, 2026
Next Earnings Date
Feb 23, 2027
Ex-Dividend Date
―

Financial Position

PTC Therapeutics as a current ratio of 2.35, with Debt / Equity ratio of -1318.51%

Current Ratio
2.35
Quick Ratio
2.27
Debt to Market Cap
0.43
Net Debt to EBITDA
1.94
Interest Coverage Ratio
5.63

Taxes

In the past 12 months, PTC Therapeutics has paid 13.97M in taxes.

Income Tax
13.97M
Effective Tax Rate
0.02

Enterprise Valuation

PTC Therapeutics EV to EBITDA ratio is 29.63, with an EV/FCF ratio of -136.20.

EV to Sales
4.47
EV to EBITDA
29.63
EV to Free Cash Flow
-136.20
EV to Operating Cash Flow
492.98

Balance Sheet

PTC Therapeutics has CHF 2.13B in cash and marketable securities with CHF 636.03M in debt, giving a net cash position of CHF 1.49B billion.

Cash & Marketable Securities
CHF 2.13B
Total Debt
CHF 636.03M
Net Cash
CHF 1.49B
Net Cash Per Share
―
Tangible Book Value Per Share
-CHF 8.59

Margins

Gross margin is 92.39%, with operating margin of 11.97%, and net profit margin of -9.17%.

Gross Margin
92.39%
Operating Margin
11.97%
Pretax Margin
-7.36%
Net Profit Margin
-9.17%
EBITDA Margin
15.10%
EBIT Margin
9.82%

Analyst Forecast

The average price target for PTC Therapeutics is CHF 84.08, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
CHF 84.08
Price Target Upside
―
Analyst Consensus
Strong Buy
Analyst Count
12
Revenue Growth Forecast
―
EPS Growth Forecast
―

Scores

Smart Score
8
AI Score
―